Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > City of Hope CF33 doses first patient

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 24, 2022 6:46pm

165 Views

Post# 34705064

RE:RE:City of Hope CF33 doses first patient

Not the same kind of virus. And it has nothing to do with it being "stronger" than pelareorep, since it isn't. It's a vaccina virus which the Mayo Clinic has demonstrated to be of lesser effectiveness when combined with CAR-T therapy whereas ONCY's pelareorep when combined with CAR-T and then given as a boost in the treatment of solid tumors, was able to produce "curative" results.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading